Amneal Pharmaceuticals, Inc. Stock News

Amneal (AMRX) delivered earnings and revenue surprises of -5.26% and 1.28%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

Companies Reporting Before The Bell • SIGNA Sports United (NYSE: SSU ) is expected to report quarterly loss at $0.04 per share on revenue of $283.61 million. • IsoPlexis (NASDAQ: ISO ) is likely to report quarterly loss at $0.68 per share on revenue of $5.45 million. • Innoviz Technologies (NASDAQ: INVZ ) is likely to report quarterly loss at $0.18 per share on revenue of $2.93 million. • International Seaways (NYSE: INSW ) is expected to report quarterly loss at $0.36 per share on revenue of $102.60 million. • Dine Brands Global (NYSE: DIN ) is estimated to report quarterly earnings at $1.27 per share on revenue of $236.67 million. • Dollar Tree (NASDAQ: DLTR ) is expected to report quarterly earnings at $1.77 per share on revenue of $7.12 billion. • Valens Semiconductor (NYSE: VLN ) is projected to report quarterly loss at $0.06 per share on revenue of $20.04 million. • Sterling Check (NASDAQ: STER ) is projected to report quarterly earnings at $0.17 per share on revenue of $152.50 million.

Amneal Pharmaceuticals (AMRX) said the U.S. FDA approved its Biologics License Application (BLA) for filgrastim-ayow, a biosimilar referencing Neupogen.The product will be marketed…

Amneal Pharmaceuticals (NYSE:AMRX) is scheduled to announce Q4 earnings results on Wednesday, Mar. 2, before market open.Consensus EPS estimate is $0.20 (+42.9% Y/Y)

Amneal (AMRX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

The U.S. Food and Drug Administration ((FDA)) approved four generic injectables products from Amneal Pharmaceuticals (AMRX).Dexamethasone sodium phosphate injection, USP 10…

Here is how Amneal Pharmaceuticals (AMRX) and Athersys, Inc. (ATHX) have performed compared to their sector so far this year.

BRIDGEWATER, N.J.--(BUSINESS WIRE)--Amneal Pharmaceuticals, Inc. (NYSE: AMRX) (the “Company”) announced today that the Company will release its fourth quarter and full year 2021 financial results

Is Amneal Pharmaceuticals (AMRX) a great pick from the value investor's perspective right now? Read on to know more.

Amneal Pharmaceuticals Inc (NYSE: AMRX) has agreed to acquire Saol's Baclofen franchise, including Lioresal, Lyvispah, and a pipeline product under development for $83.5 million in cash.  The acqui

Amneal Pharmaceuticals, Inc. (NYSE:AMRX)s share price gapped up prior to trading on Monday following insider buying activity. The stock had previously closed at $4.27, but opened at $4.51. Amneal Pharmaceuticals shares last traded at $4.42, with a volume of 11,312 shares traded. Specifically, CEO Chirag K. Patel acquired 100,000 shares of the companys stock in []

Amneal Pharmaceuticals, Inc. (NYSE:AMRX) CEO Chirag K. Patel bought 100,000 shares of the companys stock in a transaction that occurred on Wednesday, December 15th. The shares were bought at an average price of $4.13 per share, for a total transaction of $413,000.00. The transaction was disclosed in a legal filing with the SEC, which can []

Insiders are buying these penny stocks during "tax loss season" The post Penny Stocks To Buy Now According To Insiders In December 2021 appeared first on Penny Stocks to Buy, Picks, News and Informati

The Hydroxychloroquine Market report focus on the current trends of the market along with detailed analysis which provides data regarding this market rate, and it also predicts the future market growth rate. The Hydroxychloroquine Market study includes research on the

The global Shoulder Pain Treatment market size is projected to reach US$ 3.6 Billion by 2027, at a CAGR of 8.1% during 2021-2027. Globally, the geriatric population is growing at an unprecedented rate. Shoulder pain is a frequent and debilitating